<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00263861</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU6Z03</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CASE-CWRU-6Z03</secondary_id>
    <nct_id>NCT00263861</nct_id>
  </id_info>
  <brief_title>Nerve Function in Older Diabetic Patients Who Are Undergoing Chemotherapy for Metastatic Solid Tumors</brief_title>
  <official_title>Impact of Treatment With Taxane or Platinum-Containing Regimens on Peripheral Nerve Functioning in Older Cancer Patients With Diabetes: An Exploratory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Learning about the side effects of chemotherapy may help plan treatment and may&#xD;
      help patients live more comfortably.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying nerve function in older diabetic patients who are&#xD;
      undergoing chemotherapy for metastatic solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine changes in peripheral nerve function in older patients with diabetes and&#xD;
           metastatic solid tumors treated with taxane or platinum-containing chemotherapy&#xD;
           regimens.&#xD;
&#xD;
        -  Determine the extent to which age, pre-existing diabetes mellitus, and level of glycemic&#xD;
           control predict a differential pattern in outcome beyond the effect of the drugs in&#xD;
           patients treated with these regimens.&#xD;
&#xD;
        -  Develop a clinical assessment that would predict whether or not patients with diabetes&#xD;
           mellitus are more or less susceptible to the neurotoxic effects of chemotherapy.&#xD;
&#xD;
      OUTLINE: This is a longitudinal study.&#xD;
&#xD;
      Patients undergo an interview and clinical evaluation to measure demographic data, cutaneous&#xD;
      sensation, gait and balance, vibration, lower extremity muscle strength, orthostatic blood&#xD;
      pressure, and glycemic control. Patients are evaluated at baseline, every 3 weeks during&#xD;
      chemotherapy for up to 4 treatments, and at 2 months after completion of treatment.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cutaneous sensation as measured by Semmes-Weinstein monofilaments</measure>
    <time_frame>baseline, every 3 weeks for 4 courses, and then 2 months after completion of study treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Gait and balance as measured by Tinetti Performance Oriented Assessment of Gait and Balance Instrument</measure>
    <time_frame>baseline, every 3 weeks for 4 courses, and then 2 months after completion of study treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vibration as measured by tuning fork</measure>
    <time_frame>baseline, every 3 weeks for 4 courses, and then 2 months after completion of study treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lower extremity muscle strength as measured by Dynamometer</measure>
    <time_frame>baseline, every 3 weeks for 4 courses, and then 2 months after completion of study treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure changes</measure>
    <time_frame>baseline, every 3 weeks for 4 courses, and then 2 months after completion of study treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Glycemic control as measured by Glycosylated Hemoglobin Assay</measure>
    <time_frame>baseline, every 3 weeks for 4 courses, and then 2 months after completion of study treatment</time_frame>
  </primary_outcome>
  <enrollment type="Actual">14</enrollment>
  <condition>Neurotoxicity</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>management of therapy complications</intervention_name>
    <description>Patients undergo an interview and clinical evaluation to measure demographic data, cutaneous sensation, gait and balance, vibration, lower extremity muscle strength, orthostatic blood pressure, and glycemic control.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of solid tumor&#xD;
&#xD;
               -  Metastatic disease (stage IV)&#xD;
&#xD;
          -  Planning neoadjuvant or adjuvant treatment of locoregional definitive or systemic&#xD;
             therapy comprising â‰¥ 1 of the following:&#xD;
&#xD;
               -  Taxane (paclitaxel or docetaxel)&#xD;
&#xD;
               -  Platinum (cisplatin, carboplatin, or oxaliplatin)&#xD;
&#xD;
          -  Diagnosis of type I or II diabetes mellitus&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other disease that reduces peripheral nerve function (e.g., HIV/AIDS, uremia,&#xD;
             spinal injuries, alcoholism, or CNS problems)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
          -  No prior or concurrent neurotoxic drugs (i.e., vincristine)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Constance Visovsky, PhD, RN, ACNP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>December 7, 2005</study_first_submitted>
  <study_first_submitted_qc>December 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2005</study_first_posted>
  <last_update_submitted>June 10, 2010</last_update_submitted>
  <last_update_submitted_qc>June 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Constance Visovsky, PhD, RN, ACNP</name_title>
    <organization>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>neurotoxicity</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

